Ken Griffin Biomarin Pharmaceutical Inc Transaction History

Citadel Advisors LLC

  • $618 Billion
  • Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 397,847 shares of BMRN stock, worth $21.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
397,847
Previous 335,020 18.75%
Holding current value
$21.8 Million
Previous $18.4 Million 17.0%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$52.62 - $61.93 $3.31 Million - $3.89 Million
62,827 Added 18.75%
397,847 $21.5 Million
Q2 2025

Aug 14, 2025
SELL
$54.08 - $68.32 $68.1 Million - $86.1 Million
-1,260,038 Reduced 79.0%
335,020 $18.4 Million
Q1 2025

May 15, 2025
BUY
$61.25 - $72.83 $74 Million - $87.9 Million
1,207,445 Added 311.51%
1,595,058 $113 Million
Q4 2024

Feb 14, 2025
SELL
$61.93 - $70.49 $50.6 Million - $57.6 Million
-816,784 Reduced 67.82%
387,613 $25.5 Million
Q3 2024

Nov 14, 2024
BUY
$69.02 - $93.84 $44.6 Million - $60.7 Million
646,545 Added 115.9%
1,204,397 $84.7 Million
Q2 2024

Aug 14, 2024
SELL
$74.43 - $92.22 $106 Million - $131 Million
-1,417,706 Reduced 71.76%
557,852 $45.9 Million
Q1 2024

May 15, 2024
BUY
$83.81 - $99.0 $136 Million - $160 Million
1,620,613 Added 456.58%
1,975,558 $173 Million
Q4 2023

Feb 14, 2024
BUY
$76.22 - $98.51 $16.3 Million - $21 Million
213,413 Added 150.79%
354,945 $34.2 Million
Q3 2023

Nov 14, 2023
SELL
$85.07 - $94.48 $29 Million - $32.2 Million
-340,807 Reduced 70.66%
141,532 $12.5 Million
Q2 2023

Aug 14, 2023
BUY
$86.68 - $100.3 $31.1 Million - $36 Million
358,771 Added 290.34%
482,339 $41.8 Million
Q1 2023

May 15, 2023
SELL
$87.74 - $117.27 $608,301 - $813,032
-6,933 Reduced 5.31%
123,568 $12 Million
Q4 2022

Feb 14, 2023
SELL
$80.93 - $108.63 $70.6 Million - $94.7 Million
-871,813 Reduced 86.98%
130,501 $13.5 Million
Q3 2022

Nov 14, 2022
SELL
$82.16 - $96.94 $12.4 Million - $14.6 Million
-150,761 Reduced 13.07%
1,002,314 $85 Million
Q2 2022

Aug 15, 2022
SELL
$71.48 - $86.85 $67 Million - $81.4 Million
-937,328 Reduced 44.84%
1,153,075 $95.6 Million
Q1 2022

May 16, 2022
BUY
$74.28 - $92.69 $54.4 Million - $67.9 Million
732,488 Added 53.94%
2,090,403 $161 Million
Q4 2021

Feb 14, 2022
BUY
$71.72 - $91.47 $93.9 Million - $120 Million
1,308,848 Added 2667.47%
1,357,915 $120 Million
Q3 2021

Nov 15, 2021
SELL
$74.77 - $85.47 $68.1 Million - $77.9 Million
-911,095 Reduced 94.89%
49,067 $3.79 Million
Q2 2021

Aug 16, 2021
SELL
$75.51 - $84.79 $50.9 Million - $57.1 Million
-673,518 Reduced 41.23%
960,162 $80.1 Million
Q1 2021

May 17, 2021
SELL
$74.73 - $90.69 $102 Million - $123 Million
-1,361,590 Reduced 45.46%
1,633,680 $123 Million
Q4 2020

Feb 16, 2021
BUY
$72.61 - $90.2 $37.6 Million - $46.7 Million
517,914 Added 20.91%
2,995,270 $263 Million
Q3 2020

Nov 16, 2020
BUY
$71.87 - $131.03 $160 Million - $291 Million
2,222,384 Added 871.62%
2,477,356 $188 Million
Q2 2020

Aug 14, 2020
SELL
$79.55 - $124.22 $346,440 - $540,978
-4,355 Reduced 1.68%
254,972 $31.4 Million
Q1 2020

May 15, 2020
SELL
$71.37 - $96.85 $127 Million - $172 Million
-1,780,826 Reduced 87.29%
259,327 $21.9 Million
Q4 2019

Feb 14, 2020
BUY
$64.27 - $86.37 $18.2 Million - $24.4 Million
282,923 Added 16.1%
2,040,153 $172 Million
Q3 2019

Nov 14, 2019
BUY
$67.4 - $85.11 $39.6 Million - $50 Million
587,616 Added 50.24%
1,757,230 $118 Million
Q2 2019

Aug 14, 2019
BUY
$80.35 - $93.9 $3.29 Million - $3.85 Million
40,966 Added 3.63%
1,169,614 $100 Million
Q1 2019

May 15, 2019
SELL
$84.2 - $98.62 $19.3 Million - $22.6 Million
-229,037 Reduced 16.87%
1,128,648 $0
Q4 2018

Feb 14, 2019
SELL
$80.14 - $106.07 $88.2 Million - $117 Million
-1,101,023 Reduced 44.78%
1,357,685 $116 Million
Q3 2018

Nov 13, 2018
BUY
$93.92 - $105.72 $58.7 Million - $66.1 Million
625,303 Added 34.11%
2,458,708 $0
Q2 2018

Aug 10, 2018
BUY
$76.01 - $99.03 $34.8 Million - $45.3 Million
457,896 Added 33.29%
1,833,405 $0
Q1 2018

May 11, 2018
SELL
$77.67 - $92.63 $73 Million - $87 Million
-939,566 Reduced 40.58%
1,375,509 $112 Million
Q4 2017

Feb 09, 2018
BUY
$80.76 - $95.13 $54.2 Million - $63.9 Million
671,639 Added 40.87%
2,315,075 $206 Million
Q3 2017

Nov 09, 2017
BUY
$80.6 - $94.95 $132 Million - $156 Million
1,643,436
1,643,436 $153 Million

Others Institutions Holding BMRN

# of Institutions
667
Shares Held
182M
Call Options Held
1.48M
Put Options Held
957K
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $10.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email